1. President’s address: Treatment of tamoxifen-refractory breast cancer — approach by animal models

   • Yuichi Iino

   EditorialNotes Pages: 262 - 264

2. New strategies for the treatment of breast cancer

   • David J. Bentrem
   • Ruth M. O’Regan
   • V. Craig Jordan

   OriginalPaper Pages: 265 - 274

3. Treatment selection in ductal carcinomain situ

   • Monica Morrow

   OriginalPaper Pages: 275 - 282

4. Well differentiated clinging carcinoma and atypical ductal hyperplasia are synonymous

   • Vincenzo Eusebi
   • Stefano Mignani
   • Tetsunari Oyama

   OriginalPaper Pages: 283 - 284

5. E1A: Tumor suppressor or oncogene? Preclinical and clinical investigations ofE1A gene therapy

   • Naoto T. Ueno
   • Dihua Yu
   • Mien-Chie Hung

   OriginalPaper Pages: 285 - 293

6. International consensus meeting on the treatment of primary breast cancer 2001, St. Gallen, Switzerland

   • Beat Thuerlimann

   OriginalPaper Pages: 294 - 297

7. Adjuvant therapy for breast cancer — results from the USA consensus conference

   • Jeffrey S. Abrams

   OriginalPaper Pages: 298 - 304

8. Third-generation aromatase inhibitors in the treatment of advanced breast cancer

   • Jean-Marc A. Nabholtz
   • David M. Reese

   OriginalPaper Pages: 305 - 309

9. Compassionate use of humanized anti-HER2/neu protein, trastuzumab for metastatic breast cancer in Japan

   • Yutaka Tokuda
   • Yasuhiro Suzuki
   • R. Yoshiyuki Osamura

   OriginalPaper Pages: 310 - 315

10. Evaluation of HER2 status: For the treatment of metastatic breast cancers by humanized anti-HER2 monoclonal antibody (trastuzumab) (Pathological committee for optimal use of trastuzumab)

    • Shinobu Umemura
    • Goi Sakamoto
    • R. Yoshiyuki Osamura

    OriginalPaper Pages: 316 - 320

11. The worldwide perspective in the adjuvant treatment of primary lymph node positive breast cancer

    • Stefan Glück

    OriginalPaper Pages: 321 - 328

12. Aromatase and aromatase inhibitors

    • Masakazu Toi
    • Hiroko Bando
    • Shigehira Saji

    OriginalPaper Pages: 329 - 332

13. Resistant mechanisms of anthracyclines — pirarubicin might partly break through the P-glycoprotein-mediated drug-resistance of human breast cancer tissues

    • Tetsuro Kubota
    • Tomoko Furukawa
    • Masaki Kitajima

    OriginalPaper Pages: 333 - 338

14. Evolution of breast cancer management: Focus on neoadjuvant chemotherapy

    • Steven D. Heys

    OriginalPaper Pages: 339 - 350

15. 3D-MR mammography-guided breast conserving surgery after neoadjuvant chemotherapy: Clinical results and future perspectives with reference to FDG-PET

    • Seigo Nakamura
    • Hironori Kenjo
    • Koyu Suzuki

    OriginalPaper Pages: 351 - 354